Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
Identifieur interne : 000570 ( France/Analysis ); précédent : 000569; suivant : 000571Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
Auteurs : William R. Wilcox ; Maryam Banikazemi ; Nathalie Guffon [France] ; Stephen Waldek [Royaume-Uni] ; Philip Lee [Royaume-Uni] ; Gabor E. Linthorst [Pays-Bas] ; Robert J. Desnick [États-Unis] ; Dominique P. Germain [France]Source :
- American Journal of Human Genetics [ 0002-9297 ] ; 2004.
Abstract
Elsewhere, we reported the safety and efficacy results of a multicenter phase 3 trial of recombinant human α-galactosidase A (rh-αGalA) replacement in patients with Fabry disease. All 58 patients who were enrolled in the 20-wk phase 3 double-blind, randomized, and placebo-controlled study received subsequently 1 mg/kg of rh-αGalA (agalsidase beta, Fabrazyme, Genzyme Corporation) biweekly in an ongoing open-label extension study. Evidence of long-term efficacy, even in patients who developed IgG antibodies against rh-αGalA, included the continuously normal mean plasma globotriaosylceramide (GL-3) levels during 30 mo of the extension study and the sustained capillary endothelial GL-3 clearance in 98% (39/40) of patients who had a skin biopsy taken after treatment for 30 mo (original placebo group) or 36 mo (original enzyme-treated group). The mean serum creatinine level and estimated glomerular filtration rate also remained stable after 30–36 mo of treatment. Infusion-associated reactions decreased over time, as did anti-rh-αGalA IgG antibody titers. Among seroconverted patients, after 30–36 mo of treatment, seven patients tolerized (no detectable IgG antibody), and 59% had ⩾4-fold reductions in antibody titers. As of 30 mo into the extension trial, three patients were withdrawn from the study because of positive serum IgE or skin tests; however, all have been rechallenged successfully at the time of this report. Thus, enzyme replacement therapy for 30–36 mo with agalsidase beta resulted in continuously decreased plasma GL-3 levels, sustained endothelial GL-3 clearance, stable kidney function, and a favorable safety profile.
Url:
PubMed: 15154115
PubMed Central: 1182009
Affiliations:
- France, Pays-Bas, Royaume-Uni, États-Unis
- Angleterre, Auvergne-Rhône-Alpes, Grand Londres, Grand Manchester, Hollande-Septentrionale, Rhône-Alpes, État de New York, Île-de-France
- Amsterdam, Londres, Lyon, Manchester, Paris
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000036
- to stream Pmc, to step Curation: 000036
- to stream Pmc, to step Checkpoint: 003E34
- to stream Ncbi, to step Merge: 001A03
- to stream Ncbi, to step Curation: 001A03
- to stream Ncbi, to step Checkpoint: 001A03
- to stream Main, to step Merge: 008A33
- to stream Main, to step Curation: 008776
- to stream Main, to step Exploration: 008776
- to stream France, to step Extraction: 000570
Links to Exploration step
PMC:1182009Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease</title>
<author><name sortKey="Wilcox, William R" sort="Wilcox, William R" uniqKey="Wilcox W" first="William R." last="Wilcox">William R. Wilcox</name>
<affiliation><nlm:aff>NONE</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Banikazemi, Maryam" sort="Banikazemi, Maryam" uniqKey="Banikazemi M" first="Maryam" last="Banikazemi">Maryam Banikazemi</name>
<affiliation><nlm:aff>NONE</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Guffon, Nathalie" sort="Guffon, Nathalie" uniqKey="Guffon N" first="Nathalie" last="Guffon">Nathalie Guffon</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">Hôpital Edouard Herriot, Lyon, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Edouard Herriot, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Waldek, Stephen" sort="Waldek, Stephen" uniqKey="Waldek S" first="Stephen" last="Waldek">Stephen Waldek</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">Hope Hospital, Salford, Manchester, United Kingdom;</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Hope Hospital, Salford, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, Philip" sort="Lee, Philip" uniqKey="Lee P" first="Philip" last="Lee">Philip Lee</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">University College London Hospitals, London;</nlm:aff>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>University College London Hospitals</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Linthorst, Gabor E" sort="Linthorst, Gabor E" uniqKey="Linthorst G" first="Gabor E." last="Linthorst">Gabor E. Linthorst</name>
<affiliation wicri:level="3"><nlm:aff wicri:cut="; and" id="N0x91fa978.0x965c0c8">Academisch Medisch Centrum, Amsterdam</nlm:aff>
<country>Pays-Bas</country>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
<wicri:orgArea>Academisch Medisch Centrum</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Desnick, Robert J" sort="Desnick, Robert J" uniqKey="Desnick R" first="Robert J." last="Desnick">Robert J. Desnick</name>
<affiliation wicri:level="2"><nlm:aff id="N0x91fa978.0x965c0c8">Mount Sinai School of Medicine, New York;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Mount Sinai School of Medicine</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Germain, Dominique P" sort="Germain, Dominique P" uniqKey="Germain D" first="Dominique P." last="Germain">Dominique P. Germain</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">Hôpital Européen Georges Pompidou, Paris</nlm:aff>
<country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
<wicri:orgArea>Hôpital Européen Georges Pompidou</wicri:orgArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">15154115</idno>
<idno type="pmc">1182009</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182009</idno>
<idno type="RBID">PMC:1182009</idno>
<date when="2004">2004</date>
<idno type="wicri:Area/Pmc/Corpus">000036</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000036</idno>
<idno type="wicri:Area/Pmc/Curation">000036</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000036</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003E34</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003E34</idno>
<idno type="wicri:Area/Ncbi/Merge">001A03</idno>
<idno type="wicri:Area/Ncbi/Curation">001A03</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001A03</idno>
<idno type="wicri:doubleKey">0002-9297:2004:Wilcox W:long:term:safety</idno>
<idno type="wicri:Area/Main/Merge">008A33</idno>
<idno type="wicri:Area/Main/Curation">008776</idno>
<idno type="wicri:Area/Main/Exploration">008776</idno>
<idno type="wicri:Area/France/Extraction">000570</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease</title>
<author><name sortKey="Wilcox, William R" sort="Wilcox, William R" uniqKey="Wilcox W" first="William R." last="Wilcox">William R. Wilcox</name>
<affiliation><nlm:aff>NONE</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Banikazemi, Maryam" sort="Banikazemi, Maryam" uniqKey="Banikazemi M" first="Maryam" last="Banikazemi">Maryam Banikazemi</name>
<affiliation><nlm:aff>NONE</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Guffon, Nathalie" sort="Guffon, Nathalie" uniqKey="Guffon N" first="Nathalie" last="Guffon">Nathalie Guffon</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">Hôpital Edouard Herriot, Lyon, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Edouard Herriot, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Waldek, Stephen" sort="Waldek, Stephen" uniqKey="Waldek S" first="Stephen" last="Waldek">Stephen Waldek</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">Hope Hospital, Salford, Manchester, United Kingdom;</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Hope Hospital, Salford, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, Philip" sort="Lee, Philip" uniqKey="Lee P" first="Philip" last="Lee">Philip Lee</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">University College London Hospitals, London;</nlm:aff>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>University College London Hospitals</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Linthorst, Gabor E" sort="Linthorst, Gabor E" uniqKey="Linthorst G" first="Gabor E." last="Linthorst">Gabor E. Linthorst</name>
<affiliation wicri:level="3"><nlm:aff wicri:cut="; and" id="N0x91fa978.0x965c0c8">Academisch Medisch Centrum, Amsterdam</nlm:aff>
<country>Pays-Bas</country>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
<wicri:orgArea>Academisch Medisch Centrum</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Desnick, Robert J" sort="Desnick, Robert J" uniqKey="Desnick R" first="Robert J." last="Desnick">Robert J. Desnick</name>
<affiliation wicri:level="2"><nlm:aff id="N0x91fa978.0x965c0c8">Mount Sinai School of Medicine, New York;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Mount Sinai School of Medicine</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Germain, Dominique P" sort="Germain, Dominique P" uniqKey="Germain D" first="Dominique P." last="Germain">Dominique P. Germain</name>
<affiliation wicri:level="3"><nlm:aff id="N0x91fa978.0x965c0c8">Hôpital Européen Georges Pompidou, Paris</nlm:aff>
<country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
<wicri:orgArea>Hôpital Européen Georges Pompidou</wicri:orgArea>
</affiliation>
</author>
</analytic>
<series><title level="j">American Journal of Human Genetics</title>
<idno type="ISSN">0002-9297</idno>
<idno type="eISSN">1537-6605</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Elsewhere, we reported the safety and efficacy results of a multicenter phase 3 trial of recombinant human α-galactosidase A (rh-αGalA) replacement in patients with Fabry disease. All 58 patients who were enrolled in the 20-wk phase 3 double-blind, randomized, and placebo-controlled study received subsequently 1 mg/kg of rh-αGalA (agalsidase beta, Fabrazyme, Genzyme Corporation) biweekly in an ongoing open-label extension study. Evidence of long-term efficacy, even in patients who developed IgG antibodies against rh-αGalA, included the continuously normal mean plasma globotriaosylceramide (GL-3) levels during 30 mo of the extension study and the sustained capillary endothelial GL-3 clearance in 98% (39/40) of patients who had a skin biopsy taken after treatment for 30 mo (original placebo group) or 36 mo (original enzyme-treated group). The mean serum creatinine level and estimated glomerular filtration rate also remained stable after 30–36 mo of treatment. Infusion-associated reactions decreased over time, as did anti-rh-αGalA IgG antibody titers. Among seroconverted patients, after 30–36 mo of treatment, seven patients tolerized (no detectable IgG antibody), and 59% had ⩾4-fold reductions in antibody titers. As of 30 mo into the extension trial, three patients were withdrawn from the study because of positive serum IgE or skin tests; however, all have been rechallenged successfully at the time of this report. Thus, enzyme replacement therapy for 30–36 mo with agalsidase beta resulted in continuously decreased plasma GL-3 levels, sustained endothelial GL-3 clearance, stable kidney function, and a favorable safety profile.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Auvergne-Rhône-Alpes</li>
<li>Grand Londres</li>
<li>Grand Manchester</li>
<li>Hollande-Septentrionale</li>
<li>Rhône-Alpes</li>
<li>État de New York</li>
<li>Île-de-France</li>
</region>
<settlement><li>Amsterdam</li>
<li>Londres</li>
<li>Lyon</li>
<li>Manchester</li>
<li>Paris</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Banikazemi, Maryam" sort="Banikazemi, Maryam" uniqKey="Banikazemi M" first="Maryam" last="Banikazemi">Maryam Banikazemi</name>
<name sortKey="Wilcox, William R" sort="Wilcox, William R" uniqKey="Wilcox W" first="William R." last="Wilcox">William R. Wilcox</name>
</noCountry>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Guffon, Nathalie" sort="Guffon, Nathalie" uniqKey="Guffon N" first="Nathalie" last="Guffon">Nathalie Guffon</name>
</region>
<name sortKey="Germain, Dominique P" sort="Germain, Dominique P" uniqKey="Germain D" first="Dominique P." last="Germain">Dominique P. Germain</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Waldek, Stephen" sort="Waldek, Stephen" uniqKey="Waldek S" first="Stephen" last="Waldek">Stephen Waldek</name>
</region>
<name sortKey="Lee, Philip" sort="Lee, Philip" uniqKey="Lee P" first="Philip" last="Lee">Philip Lee</name>
</country>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Linthorst, Gabor E" sort="Linthorst, Gabor E" uniqKey="Linthorst G" first="Gabor E." last="Linthorst">Gabor E. Linthorst</name>
</region>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Desnick, Robert J" sort="Desnick, Robert J" uniqKey="Desnick R" first="Robert J." last="Desnick">Robert J. Desnick</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000570 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000570 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= France |étape= Analysis |type= RBID |clé= PMC:1182009 |texte= Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:15154115" \ | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |